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Abstract: Skeletal muscle represents one of the most plastic tissues of our body thanks to the presence 
of heterogeneous population of myofibers that confer to skeletal muscle the functional plasticity neces-
sary to modulate its morpho-fuctional properties in response to a wide range of external factors. Thus, 
alteration in fiber type composition represents a major component in muscle wasting associated with muscle diseases. 
Several mechanisms have been proposed to account for the alteration in the morpho-functional properties of skeletal mus-
cle under pathological conditions. In this review we will discuss the potential catabolic mediators of muscle atrophy and 
wasting. 
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INTRODUCTION 
 Skeletal muscle is composed of multinucleated myofi-
bers, arising from mononucleated precursor cells. Under 
physiologic conditions, such as exercise, change in hormone 
levels, oxygen and nutrient supply, skeletal muscle is able to 
change their morpho-functional properties and to adapt to 
external factors. Moreover, after development, skeletal mus-
cle maintains the capacity to regenerate in response to differ-
ent stimuli, recapitulating many aspects of development. 
However, The functional performance and the regenerative 
capacity of skeletal muscle tissues declines during post-natal 
life and they are compromised in different diseases. 
 In this review we will discuss the general basis of muscle 
development and the molecular mechanisms associated with 
muscle atrophy and wasting. 
MOLECULAR CONTROL OF MUSCLE DEVELOP-
MENT 
 Muscle development is the result of the combined action 
of several factors, emanating from neural tube, dorsal ecto-
derm and lateral mesoderm, ultimately leading to the genera-
tion of heterogeneous population of muscle fibers [1].  
 The myogenic determination factors (MDFs), namely 
Myf-5, MyoD, myogenin and MRF4, represent muscle-
restricted members of transcription factors that orchestrate a 
specific program of muscle gene expression in a temporally 
and spatially distinct pattern (Fig. 1) [2-9]. In particular, 
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MyoD and myf-5 are required for the commitment of precur-
sor proliferating cells to the myogenic lineage, whereas my-
ogenin and MRF4 control the differentiation of committed 
cells into mature myofibers. The myogenic program is com-
pleted with the innervation of myofibers by motor neurons 
during a period known as maturation, at the end of which the 
functional performance and the heterogeneity of skeletal 
muscle are modulated by nerve activity. It has been also re-
ported that the myogenic program is modulated at epigenetic 
level, suggesting the presence of molecular circuitry of tran-
scriptional regulation based on modulation of chromatin 
structure by reversible acetylation of histone tails [10].  
 Although the role of MDFs during embryonic develop-
ment has been extensively investigated, less is known about 
their role during post-natal life. MyoD, myf-5 and myogenin 
expression decline during the first week of post-natal life, 
whereas MRF4 is predominantly expressed in adult skeletal 
muscle. However under certain conditions, such as aging, 
diseases, and injury, the re-activation of MDFs expression 
recapitulate the myogenic program [11-13].  
MOLECULAR ORGANIZATION OF SKELETAL 
MUSCLE TISSUE 
 The cytoskeletal proteins, which can be subdivided in 
four major groups: the contractile sarcomeric, the intra-
sarcomeric, the peri-sarcomeric and the sub-sarcolemmal 
proteins [14], play important role in the maintenance of mus-
cle integrity and in the modulation of several signal transduc-
tion pathways; thus alteration in one or more cytoskeletal-
associated components leads to muscle diseases (Fig. 2). 
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Fig. (1). Schematic representation of muscle formation during embryonic development. Developmental myogenesis occurs in three dis-
tinct stages: commitment, differentiation and maturation. Skeletal muscles are derived from somites which receive signals from the neighbor-
ing tissues, which in turn induce the activation (blue arrows) of muscle-regulatory factors (MyoD, Myf5, myogenin, and MRF4). Sonic 
hedgehog Shh (Shh) (from the notochord) and Wingless-related integration site (Wnt) Wnt1/3, Wnt11 and insulin-like growth factors (IGFs) 
(from dorsal neural tube) signaling have been shown to regulate the expression of Myf5. Pax3 and Myf5 independently regulate MyoD ex-
pression, whereas Myf5 regulates the transient expression of MRF4. Myf5 and MyoD independently activates the expression of Myogenin, 
which promotes the expression of Myosin (modified from [13]). 
 
 
 
Fig. (2). The molecular organization of cytoskeleton protein. The dystrophin protein is associated with the dystroglycan complex and con-
nects the cytoskeleton of a muscle fiber to its surrounding extracellular matrix. Mutations in various members of these proteins are associated 
with different muscle disorders (text in red). 
 
 Actin and myosin myofilaments belong to the contractile 
sarcomeric cytoskeleton and represent the functional core of 
muscle contraction; titin, nebulin, tropomyosin and actinin 
are classified as intra-sarcomeric protein; desmin-intermediate 
filament is a component of the peri-sarcomeric cytoskeleton, 
whereas the sub-sarcolemmal cytoskeleton includes sar-
colemma-associated protein, such as dystrophin, vinculin, 
integrins, α-actinin, and ankyrin. Among the proteins that 
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are associated with the plasma membrane, the dystroglycan 
complex, formed by the subunits α and β dystroglycan, bind 
to the dystrophin protein and plays a critical role in the con-
nection of the cytoskeleton of a muscle fiber to its surround-
ing extracellular matrix [15] (Fig. 2).  
 Other structural components of skeletal muscle are the 
caveolins, the principal components of the caveolae, vesicu-
lar invaginations of the plasma membrane, which participate 
to trafficking events and signal transduction processes [16]. 
Among caveolin, caveolin-3 is localized to the sarcolemma 
where it forms a complex with cytoplasmic signaling mole-
cules (G-proteins and Src-like kinases), dystrophin and its 
associated glycoproteins, such as alpha-sarcoglycan and 
beta-dystroglycan [17] (Fig. 2). It has also been demon-
strated that deficiency of caveolin-3 is causally linked to 
limb girdle muscular dystrophy (LGMD) [18]. 
 The structural integrity of complex cytoskeleton molecu-
lar organization is therefore a prerequisite for the efficient 
mechanical function of skeletal muscle; thus alterations in 
cytoskeletal organization lead to muscle wasting and dis-
eases. 
THE MOLECULAR MECHANISMS OF MUSCLE 
WASTING 
 A general feature associated with several pathologic con-
ditions is the loose of adaptability of skeletal muscle leading 
to wasting, a process in which the delicate balance between 
anabolic and catabolic process is impaired [19, 20]. Among 
different signalling, Calcium (Ca2+) is an important intracel-
lular messenger, controlling numerous cellular processes, 
including proliferation, cell growth, differentiation, and gene 
transcription, through the activation of so called “toolkit”, 
which comprises an array of signalling, homeostatic and 
sensory mechanisms [21]. However, defects in signalling 
“toolkit” can compromise the functional performance of 
muscle and activate proteolytic systems, leading to muscle 
wasting [22]. For example, it has been demonstrated that in 
Duchenne muscular dystrophy, the absence of dystrophin 
causes alterations in intracellular Ca2+ leading to an imbal-
ance between muscle protein synthesis and protein degrada-
tion, culminating in necrosis, fibrosis, and shift in fiber con-
tent [23]. In other pathologic conditions, such as sarcopenia, 
the accumulation of free radicals promotes an increase in 
calcium concentration, which induces the activation of pro-
teolytic systems with the consequence of an increase in pro-
tein degradation and reduction in protein synthesis [24]. 
 Among proteolytic systems calpain-, ubiquitin- caspase- 
and autophagy-mediated protein and organelles degradation 
are the principal pathways activated in several pathologies, 
leading to myofiber degeneration, wasting and impaired 
muscle regeneration. 
THE CALPAIN PATHWAY 
 Calpains, which have been identified in many organisms 
[25], are calcium-activated cysteine proteases characterized 
by the presence of two subunits, an 80kDa large subunit that 
contains protease activity and a 30kDa smaller subunit, func-
tioning as a regulator of calpain activity [26]. Based on Ca2+ 
concentration dependence, two ubiquitous calpain isoforms, 
µ and m, are well characterized, and are commonly referred 
as the ubiquitous/conventional/typical calpains. Among the 
different subtypes, calpain 3 is predominantly expressed in 
skeletal muscle and it maintains proteolytic activity at 
physiological Ca2+ [27]. More recently, it has been demon-
strated that calmodulin (CaM), a known transducer of the 
calcium signal, binds and facilitates Calpain 3 autolytic acti-
vation, providing additional insights into the mechanisms of 
Calpain 3 regulation in skeletal muscle [28]. At physiologic 
levels, calpains participate in many cellular processes, in-
cluding cytoskeletal remodeling [29], cell mobility [30], 
myofibril maintenance [31], signal transduction [32] cell 
cycle progression [33], regulation of gene expression [34], 
apoptosis [35], and long term potentiation [36]. Calpains are 
also activated by several stimuli in which intracellular Ca2+ 
homeostasis is affected, causing sarcomeric alterations [37], 
mitochondrial swelling, sarcoplasmic reticulum vacuoliza-
tion [38, 39] and disruption of the contractile tissue [40] 
(Fig. 3). 
 Calpains are preferentially localized in the Z disk of the 
sarcomere [41] where they initiate the proteolytic cleavage 
of muscle proteins that anchor the sarcomere, including titin, 
nebulin, desmin, filamin, troponin and tropomyosin, causing 
the complete disassembly of myofibrils and loss of the Z 
disk [42, 43]. Fodrin, the non-erythroid spectrin protein and 
a major component of the cortical cytoskeleton of most eu-
karyotic cells including muscle cells, is another molecular 
target of calpains [42]. Cleavage of fodrin accompanies 
apoptosis induced by treatment of cells with staurosporine, 
glucocorticoid, or synthetic ceramide [43, 44], all factors that 
affect muscle physiology and myofibers survival. 
 The activity of calpains is regulated by the endogenous 
inhibitor calpastatin which prevents both enzyme activation 
and expression of catalytic activity [45] (Fig. 3). The interac-
tions between calpastatin and calpains are modulated by in-
tracellular Ca2+concentration [46].  
 In contrast to other proteolytic systems, calpains cleave 
target proteins at specific sites, leaving large polypeptide 
fragments with altered physiological properties. In addition, 
post-translational modifications provide a mechanism of 
“marking” specific proteins for calpain degradation, as for 
troponin T and I that are phosphorylated by protein kinase A 
and C, which alter the sensitivity of the protein to calpain 
degradation [47]. The activity of calpains is also associated 
with neutrophil accumulation during exercise [48] and can 
cause proteolysis and muscle fiber degradation in Duchenne 
and Becker muscular dystrophies (DMD/BMD) [49], sug-
gesting a role for calpains in muscle injury and in the patho-
genesis of muscle diseases. Of interest is the observation that 
calpain3 is associated with limb-girdle muscular dystrophy 
type 2A [50], and might control myoblast fusion and matura-
tion, suggesting a role in muscle function [51].  
 More recently, two sarcomeric tropomodulin (Tmod) 
isoforms, Tmod1 and Tmod4, have been characterized, 
which represent novel proteolytic targets of m-calpain [52]. 
The levels of m-calpain resulted elevated in dystrophic so-
leus muscle of mdx mice and were associated with loss of 
Tmod1 from the thin filament pointed ends, suggesting that 
Tmod proteolysis, by m-calpain, represents a novel mecha-
nisms that may contribute to DMD pathology [52].  
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 In other reports, the catabolic activity of calpains, along 
with the ubiquitin-proteasome pathway, has been associated 
with muscle atrophy induced by chronic hypobaric hypoxia 
and with sarcopenia [53]. 
 Sarcopenia is a pathologic consequence of aging, associ-
ated with loss of muscle mass and function. It has been dem-
onstrated that sarcopenia is greatly reduced by muscle-
specific overexpression of calpastatin. Of note, the activity 
of calpain can be regulated by nitric oxide (NO) through S-
nitrosylation. Interestingly, Samengo et al [54] demonstrated 
that neuronal nitric oxide synthase (nNOS), the primary 
source of muscle NO, is loss during aging, whereas expres-
sion of a muscle-specific nNOS transgene restores calpain S-
nitrosylation in aging muscle and prevents sarcopenia. 
 Other reports provided additional insights into the patho-
genic role of calpain in sarcopenia. One of the leading 
mechanistic theories for aging is the oxidative damage hy-
pothesis, based also on the evidences that age-related 
changes accelerate with elevated oxidative stress [55, 56]. It 
has been demonstrated that calpains activate the degradation 
of oxidated myofibrillar proteins [57], suggesting a mecha-
nistic link between oxidative stress and accelerated myofi-
brillar proteolysis in disuse muscle atrophy [57, 58]. In addi-
tion, it has been reported that the expression of a calpastatin 
transgene, the endogenous inhibitor of calpains, attenuates 
muscle wasting associated to muscle disuse and prevents the 
shift from slow to fast of muscle fiber type in muscle unload-
ing [59].  
 Collectively these studies demonstrate that calpains play 
a key role in both muscle homeostasis and diseases. Future 
study will be needed to test the feasibility of Calpains in 
gene therapeutic applications and to identify their in vivo 
substrates. 
THE UBIQUITIN-PROTEASOME SYSTEM 
 One of the signal transduction pathways that mediates the 
turnover of muscle protein is the ubiquitin-proteasome sys-
tem, which is also over-activated in several conditions lead-
ing to muscle wasting (e.g. glucocorticoid treatment, sepsis, 
fasting, cancer, and acidosis) [60-63]. The pathway involves 
an enzymatic cascade starting with the conjugation of protein 
substrates with ubiquitin and terminating with the degrada-
tion of targeted protein to small peptides and amino acids 
(Fig. 4). Activated ubiquitin is then transferred by E1 to a 
carrier protein E2 (ubiquiting-conjugating enzyme); in the 
last step the ubiquitin-protein ligases E3 recognize the pro-
tein which will be ubiquitinated and catalyze the covalent 
interaction between the carboxyl group of ubiquitin and the 
ε-amino group of lysine in the protein substrate (Fig. 4). 
These reactions are repeated to form an ubiquitin chain and 
finally the ubiquitin-conjugated proteins are transferred, in 
an ATP-dependent reaction, in the 26S proteasome complex 
where the proteins are degraded (Fig. 4). The ubiquitin itself 
is then released and reused for a new enzymatic reaction 
(Fig. 4).  
 It has been demonstrated that several pathologic condi-
tions, associated with muscle atrophy, over-activate an “at-
rophy program” in which the ubiquitin-proteasome pathway 
represents the major player [64-66]. The muscle-specific 
ubiquitin-ligases, atrogin-1 (MAFbx) and Muscle RING 
Finger 1 (MuRF1) are up-regulated in muscle atrophy [67-
69]. Indeed, knockout animals deficient in either MAFbx or 
MuRF1 are resistant to atrophy [68], whereas their overex-
 
 
Fig. (3). Schematic representation of the calpain-mediated alteration in skeletal muscle leading to atrophy and wasting. Calpains are 
Ca2+-activated cysteine proteases, which might target different intracellular components, causing disruption of the contractile tissue, mito-
chondrial swelling, sarcoplasmic reticulum vacuolization, and sarcomeric alterations, leading to muscle atrophy and wasting. Calpastatin 
represents the negative regulator of calpain activity. 
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pression produce atrophy and disrupts the integrity of sar-
comeric structure and alter the components of thick filaments 
[69]. Several factors affect muscle homeostasis [69]; among 
these, glucocorticoids stimulate muscle protein breakdown, 
activating the ubiquitin-proteasome proteolysis and promot-
ing muscle atrophy [69]. The reduction in anabolic factors, 
such as the insulin-like growth factors-1 (IGF-1), represents 
another potent stimulus for the activation of ubiquitin-
proteasome pathway and therefore protein degradation. IGF-
1 has been implicated in many anabolic pathways in skeletal 
muscle [70-73] and, considering that its expression declines 
with age, it has been suggested that this down regulation is 
likely to be causally linked to the progress of muscle atrophy 
in senescence, limiting the ability of skeletal muscle to sus-
tain regeneration and repair [72-76]. It has been reported that 
the decreased activity of the IGF-1/PI3K/AKT signaling 
pathway can lead to muscle atrophy [77], via the activation 
of the “atrophy program”. One downstream target of the 
IGF-1/PI3K/AKT pathway is the Forkhead box O (FoxO) 
class of transcription factors [78, 79]. AKT blocks, by phos-
phorylation, the function of FoxO factors, leading to their 
sequestration in the cytoplasm [80]. Reduction in anabolic 
factors, including IGF-1, causes the inhibition of the 
PI3K/AKT pathway. In such conditions, the dephosphory-
lated active form of FoxO factors enter to the nucleus where 
transactivate the expression of atrogin-1 and MuRF1 [79]. Of 
note, kinases downstream of AKT, including GSK3β, as well 
as the MEK and calcineurin systems, which have been im-
plicated in the regulation of muscle fiber size [77, 81, 82] do 
not have direct roles in the regulation of atrogin-1 expression 
[79]. More recently, two additional targets of FoxO activity 
have been identified: SMART (Specific of Muscle Atrophy 
and Regulated by Transcription) and MUSA1 (muscle ubiq-
uitin ligase of SCF complex in atrophy-1) [83, 84]. MUSA1 
is a novel ubiquitin ligase that plays a critical role for the 
induction of muscle atrophy during denervation and fasting 
[81, 82]. Inhibition of MUSA1, by RNAinterference, pre-
vents muscle atrophy, whereas excessive MUSA1 induction 
exacerbates muscle loss, causing muscle cachexia [81]. It has 
been also demonstrated that FoxO3 regulates another prote-
olytic pathways, namely autophagy (discussed below), coor-
dinating the proteasomal-dependent removal of proteins with 
the autophagy-dependent clearance of organelles. 
THE CASPASE PATHWAY 
 Caspases represent a central component of the proteolytic 
system and apoptotic machinery dysregulated in several dis-
eases, including cancer and muscular dystrophies [85]. 
Caspases are all expressed as inactive proenzymes and are 
activated after cleavage at specific aspartate residues, gener-
ating the active product having lower molecular weight [86]. 
Caspases are classified in two major groups: the initiator 
caspases, which include caspase-2, -8, -9 and -10, that initi-
ate the proteolitic cascade, and the effector caspases that 
include caspases-3, -6 and -7. Once activated, the effector 
caspases are responsible for the proteolytic cleavage of a 
broad spectrum of cellular targets, which ultimately leads to 
cell death [86] (Fig. 5). While the initiator caspases are auto-
activated, the activation of an effector caspase is carried out 
by an initiator caspase. The activation of caspases can be 
triggered by either extrinsic death stimuli in which specific 
ligands triggers a cascade of events leading to the activation 
of initiator caspases, or alternatively by intrinsic death stim-
uli inducing mitochondrial release of cytochrome c and for-
mation of the apoptosome upon cytochrome c binding to 
Apaf1 (Fig. 5) [85, 86]. 
 A key role of caspases is to inactivate proteins that pro-
tect living cells from apoptosis. It has been reported that the 
cleavage of ICAD [87, 88], an inhibitor of the caspase-
activated deoxyribonuclease (CAD), leads to DNA fragmen-
tation. In non-apoptotic cells, CAD is present as an inactive 
complex with ICAD. Under apoptotic stimuli, caspases inac-
tivate ICAD leaving CAD free to fragment DNA. Caspases 
also cleave structural proteins of the nucleus and cytoskele-
ton. Proteolysis of lamins promotes the destruction of nu-
clear lamina and allows chromatin condensation [89, 90], 
whereas the cleavage of desmin, by caspase 6, generates a 
small product (N-desmin) that activates apoptotic pathways 
[91]. Similarly, the caspase-dependent cleavage of other pro-
teins, such as gelsolin, which controls cell motility and mor-
phology, or β-catenin, generates fragments that might alter 
cell-cell contacts and cell-matrix focal adhesions, DNA re-
pair, mRNA splicing, and DNA replication, promoting apop-
tosis [85, 92, 93].  
 
 
Fig. (4). Schematic representation of the ubiquitin-mediated protein degradation. Ubiquitin is activated by the ubiquitin-activating en-
zyme-E1 and then transferred to a ubiquitin-conjugating enzyme-E2. The E2 enzyme and the protein substrate both bind to the ubiquitin-
protein ligase-E3. The protein substrate becomes polyubiquitinated; the polyubiquitin chain functions as a signal to target the polyubiquiti-
nated protein substrate to the 26S proteasome, which represents a multicompartmentalized protease formed by two subunits: 20S and 19S, 
for degradation, generating short peptides and free ubiquitin that can be further reused.  
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 Caspase-mediated apoptosis is also associated with dif-
ferent muscular diseases, including Duchenne and faci-
oscapulo-humeral dystrophies [94]. One of the proposed 
mechanisms that mediates the activation of caspase pathway 
in muscular dystrophy is the endoplasmic reticulum (ER) 
stress, caused by calcium dysregulation, hypoxia/ischaemia 
and oxidative stress [95-98]. ER stress causes alteration in 
protein folding; thus unfolded and misfolded proteins accu-
mulate in the ER lumen, triggering the apoptotic pathway 
(reviewed in [99]). Of note, ER stress activates the initiator 
caspases-12 and-4, which localized to the cytoplasmic face 
of the ER membrane [100, 101] and in turn activate caspase-
9 and caspase-3, leading to apoptosis [102, 103]. Activated 
caspase-12 can also translocates to the nucleus, and may 
carry out apoptotic events directly [104], whereas deleting 
caspase-12 preserves muscle function in the mdx dystrophic 
mouse model, resulting in recovery of both specific force 
generation and resistance to eccentric contractions [105]. 
 Caspases are also involved in the catabolic processes of 
skeletal muscle associated with cancer cachexia and in the 
inhibition of muscle differentiation [106]. The inflammatory 
cytokines tumor necrosis factor-alpha (TNFα) induces mus-
cle proteolysis associated with cancer and negatively modu-
lates skeletal muscle differentiation [107-109]. TNFα can 
activate NF-kB, one of the central players implicated in 
muscle wasting in different pathologic conditions [110], and 
can inhibit muscle differentiation upon the expression of 
PW1 [109, 111]. It has been suggested that the Jak2/Stat3 
singnaling pathway is involved in cancer cachexia [112-
114]. Accordingly, molecular inducers of this pathway, such 
as IL-6, oncostatin M, leukemia inhibitory factor (LIF), and 
ciliary neurotrophic factor (CNTF), have each been reported 
to cause loss of muscle mass [115, 116]. Moreover, pharma-
cological and/or genetic inhibition of Jak/Stat3 signaling, or 
IL-6 activity, counteract cancer-associated cachexia, age-
induced sarcopenia, and muscular dystrophy, stimulating 
muscle regeneration [112, 113, 117-120]. Silva and co-
workers [121] have demonstrated that p-Stat3, by binding to 
the caspase-3 promoter, stimulates caspase-3 transcription. It 
has been proposed that caspase-3 promotes muscle protein 
losses in two ways: it first cleaves the complex structure of 
actomyosin and myofibrillar proteins to produce substrates 
for the ubiquitin proteasome system and then caspase-3 
stimulates 26S proteasome activity by cleaving some regula-
tory subunits of the 19S particle [121-123]. Inhibition of 
Stat3 activation suppresses caspase-3 and the ubiquitin-
proteasome system, leading to preservation of muscle mass 
in cancer cachexia [121]. 
 Interestingly, the discovery that the activities of caspase-
3 and the ubiquitin-proteasome system work together to 
stimulate muscle wasting indicates how increased proteolysis 
can be achieved while maintaining specificity [124]. 
THE AUTOPHAGIC PATHWAY 
 Autophagy is a critical mechanism for all eukaryotic or-
ganisms, since it ensures specific cytosolic rearrangements 
needed for proliferation, death, and differentiation during 
embryogenesis and postnatal development [125]. Autophagy 
is activated as an adaptive catabolic process in response to 
different metabolic stress, including fasting, growth factor 
depletion, hypoxia, denervation, etc. Whereas basal level of 
autophagy is essential for physiological turnover of old and 
damaged organelles, the activation of autophagic pathway 
beyond a certain threshold may promote cell alterations by 
causing the collapse of cellular functions as a result of cellu-
lar atrophy [126, 127].  
 We recently demonstrated that autophagy plays a domi-
nant role in the promotion of muscle atrophy associated with 
local alteration in the activity of the antioxidant enzyme 
SOD1 [128, 129]. In particular, oxidative stress might acti-
vate the transcription factor FoxO3 that in turn promotes the 
transcriptional activation of autophagy-related genes, such as 
LC3, cathepsin L and Bnip3. In addition, our study docu-
mented how the T-tubule might be the potential donor of 
membranes forming the autophagic vesicles. In the auto-
 
 
Fig. (5). Schematic representation of the caspase-mediated cell death. Caspases can be activated by either extrinsic or intrinsic death 
stimuli. Extrinsic death signals promote the activation of initiator caspases, which in turn induce the effector caspases, responsible for the 
proteolytic cleavage of cellular targets. Intrinsic death stimuli, such as the cytosolic release of cytochrome c in response to mitochondrial 
damage. The cytochrome c binds to Apaf1 and promotes the recruitment of procaspases to form the apoptosome, resulting in the activation of 
initiator caspases and then to the induction of effector caspases and subsequently to cell death. 
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phagy-lysosome system, small ubiquitin-like molecules 
(among which LC3) are transferred to isolation membranes 
to trigger their growth and commitment degradation of the 
inner membranes of the autophagosome and of the engulfed 
proteins [130-133] (Fig. 6).  
 The search for muscle markers associated with protein 
breakdown has revealed that under pathologic conditions the 
increased expression of lysosomal cystein endopeptidase 
cathepsin L and LC3 is associated with skeletal muscle wast-
ing [134-136]. In fact, it has been reported that cathepsin L 
expression is up-regulated in skeletal muscle of animals 
bearing sepsis and cancer and in rat treated with the gluco-
corticoid analogue dexamethasone [134]. On the other hand, 
cathepsin L expression decreases in tumor-bearing animals 
treated with an inhibitor of tumor necrosis factor-alpha 
(TNF-α). These studies suggest that cathepsin L expression 
represents an early marker of muscle wasting associated with 
the activation of proteolytic pathways. 
 As mentioned above, FoxO3 is necessary and sufficient 
for the induction of autophagy in skeletal muscle under dif-
ferent pathologic conditions [79, 137]. Interestingly, a major 
effector of FoxO3-mediated autophagy in skeletal muscle is 
Bnip3, since Bnip3 expression is induced by FoxO3, 
whereas Bnip3 knockdown blocks FoxO3-induced auto-
phagy [135, 137]. 
 An alternative pathway that has been described to induce 
autophagy independently of FoxO3 is the p38 αβ MAPK 
[138], although the specific transcription factors downstream 
of p38MAPK remains unclear. 
 Recently, we published a set of guidelines for the exami-
nation of macroautophagy and related processes [139]. This 
because there is a difference between measurements that 
monitor the numbers or volume of autophagic elements vs. 
those that measure flux through the autophagy pathway. 
Thus, the appearance of more autophagosomes does not nec-
essarily equate with more autophagy. In fact, in many cases, 
autophagosomes accumulate because of a block in traffick-
ing to lysosomes without a concomitant change in auto-
phagosome biogenesis, whereas an increase in 
autolysosomes may reflect a reduction in degradative activity 
[139]. 
CONCLUSIONS 
 The continual synthesis and degradation of cell proteins 
are the result of normal intracellular metabolism and repre-
sent an important homeostatic function of muscle tissue. 
Muscle wasting, in contrast, is a process in which the deli-
cate balance between anabolic and catabolic process is im-
paired. In this review we described the major proteolytic 
systems that are over-activated in muscle pathologies, al-
though the identification of the exact signaling cascades that 
regulate muscle wasting is only at the initial step. Different 
studies indicate that the development of muscle wasting is a 
multifactorial process and believed to be the result of both 
intrinsic factors, involving changes in molecular and cellular 
levels, and extrinsic ones, such as nutrition and exercise. 
Modulation of these pathways therefore comprises an attrac-
tive target for drug intervention. Therefore, it is of funda-
mental importance to gain greater knowledge about the mo-
lecular processes controlling the debilitating conditions to 
find effective countermeasures. 
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